- 中文名稱
Anti-Human B7-H1/PD-L1
- 英文名字
- Anti-Human B7-H1/PD-L1
- 供應(yīng)商
- ReliaTech
- 產(chǎn)品貨號(hào)
- 102-P23
- 產(chǎn)品報(bào)價(jià)
- ￥詢價(jià)/100ug
- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購(gòu)買方式
- 90%產(chǎn)品中國(guó)有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868
- 產(chǎn)品新聞
- 背景資料
- Human B7 homolog 1 (B7H1), also called programmed death ligand 1 (PDL1) and programmed cell death 1 ligand 1 (PDCD1L1), is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. Other family members include B71, B72, B7H2, PDL2 and B7H3. B7 proteins are members of the immunoglobulin (Ig) superfamily, their extracellular domains contain 2 Ig-like domains and all members have short cytoplasmic domains. Among the family members, they share about 20 25% amino acid identity. Human and mouse B7H1 share approximately 70% amino acid sequence identity. B7H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. The B7H1 gene encodes a 290 amino acid (aa) type I membrane precursor protein with a putative 18 aa signal peptide, a 221 aa extracellular domain, a 21 aa transmembrane region, and a 31 aa cytoplasmic domain. Human B7H1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. B7H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. B7H1 expression is also induced in dendritic cells and keratinocytes after IFNγ stimulation. Interaction of B7H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7H1: PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.
- 應(yīng)用類型
- ELISA, WB
- 免疫原
- 該Anti-Human B7-H1/PD-L1的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 來源宿主
- Rabbit
- 反應(yīng)性
- 該Anti-Human B7-H1/PD-L1的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 保存建議
- 該Anti-Human B7-H1/PD-L1的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
- 其他
- ReliaTech全稱為受體配體技術(shù)有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國(guó)不倫瑞克，是一家后基因組生物技術(shù)公司。ReliaTech主要專注于受體和配體的發(fā)現(xiàn)與研究。此外，ReliaTech也開發(fā)應(yīng)用于血管與淋巴管生成研究的相關(guān)高品質(zhì)試劑。目前ReliaTech提供近2800款產(chǎn)品，產(chǎn)品線主要包括重組蛋白(細(xì)胞因子、生長(zhǎng)因子、可溶性受體)、抗體、ELISA試劑盒等。
- 注意
-
該頁面的中文產(chǎn)品信息的翻譯，僅供參考。準(zhǔn)確的產(chǎn)品信息請(qǐng)以廠家的英文說明書為準(zhǔn)。下單前，請(qǐng)瀏覽說明書確認(rèn)。
-
